ISR IsoRay Inc

  

United States Securities And Exchange Commission
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): December 18, 2015  

 

ISORAY, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota	001-33407	41-1458152
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

 

350 Hills Street, Suite 106, Richland, Washington 99354

(Address of principal executive offices) (Zip Code)

 

(509) 375-1202

(Registrant’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

ITEM 1.01 Entry into a Material Definitive Agreement

 

On December 18, 2015, IsoRay Medical, Inc. (“Medical”), a wholly owned subsidiary of IsoRay, Inc. (the “Registrant”), entered into an Addendum No. 1 (the “Addendum”) to its existing supply contract (the “Agreement”) with Joint Stock Company “Institute of Nuclear Materials”, a Russian company. Through the Addendum, the Agreement’s term was extended through March 31, 2016 solely to permit ongoing payments for orders made by Medical through December 31, 2015 (the intended last order date under the Agreement). Beginning January 1, 2016, all new orders and payments for those new orders will be made pursuant to the terms of Medical’s new supply agreement with its new Russian supplier, JSC Isotope, as disclosed in the Registrant’s Form 8-K filed on December 21, 2015.

 

ITEM 9.01 Exhibits

 

(c)

Exhibits

 

10.86

Addendum No. 1, dated December 18, 2015, to Contract, dated January 12, 2015, by and between IsoRay Medical, Inc. and Joint Stock Company “Institute of Nuclear Materials”

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated:  December 30, 2015
	IsoRay, Inc., a Minnesota corporation
	By:	/s/ Dwight Babcock
		Dwight Babcock, CEO

 

 

Exhibit 10.86

 

Addendum No.1 to

Contract №840/08624332/1620 -15 Date of signature: 18 December 2015

THE SELLER/THE MANUFACTURER Open Joint Stock Company «Institute of The Nuclear Materials» (JSC «INM») 624250, Russia, Sverdlovsk Region, Zarechniy, PO Box 29 Phone.: 7 (34377) 362 64 FAX: 7 (34377) 733 46 E-mail: shipping@inm-rosatom.ru

THE BUYER The Company IsoRay Medical Inc. 350 Hills Street, Suite 106 Richland, WA 99354-5411 USA

THE CONSIGNEE The Company IsoRay Medical Inc. 350 Hills Street, Suite 106 Richland, WA 99354-5411 US Airport of destination: Seattle or Portland, USA

NOTIFICATION FedEX Trade Networks 16353 NE Cameron Blvd Portland, Oregon 97230 USA Phone: +1503-255 1391 ext.14

THE END USER The Company IsoRay Medical Inc. 350 Hills Street, Suite 106 Richland, WA 99354-5411 USA

THE SHIPPER Joint Stock Company «Institute of Nuclear Materials» (JSC «INM») 624250, Russia, Sverdlovsk Region, Zarechniy, PO Box 29 Phone.: 7 (34377) 362 64 FAX: 7 (34377) 733 46 E-mail: shipping@inm-rosatom.ru

TERMS OF DELIVERY CPT airport Seattle or Portland, USA (Incoterms 2010)

THE BUYERS and THE SELLERS have mutually agreed to prolong the period of validity of the present contract till the 31st of March, 2016.

All other terms and conditions of Contract №840/08624332/1620 -15 remind unchanged

The present Addendum is an integral part of the above mentioned contract and may be signed by E-mail.

 

THE SELLERS		THE BUYERS
/s/ Dmitrii  Markov		/s/ Dwight Babcock
Director General JSC INM		Dwight Babcock
		CEO IsoRay Medical